AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer

AstraZeneca and Merck's ovarian cancer drug Lynparza has received U.S. regulatory approval for the treatment of advanced pancreatic cancer, cementing its lead in a niche category of cancer treatments.

from Reuters: Health News https://ift.tt/2u3L38V